Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI

The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialog...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent, Marie, Quéméner, Agnès, Jacques, Yannick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857326/
https://www.ncbi.nlm.nih.gov/pubmed/24349876
http://dx.doi.org/10.4161/onci.26441
_version_ 1782295152385064960
author Vincent, Marie
Quéméner, Agnès
Jacques, Yannick
author_facet Vincent, Marie
Quéméner, Agnès
Jacques, Yannick
author_sort Vincent, Marie
collection PubMed
description The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease.
format Online
Article
Text
id pubmed-3857326
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38573262013-12-12 Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI Vincent, Marie Quéméner, Agnès Jacques, Yannick Oncoimmunology Author's View The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease. Landes Bioscience 2013-11-01 2013-10-09 /pmc/articles/PMC3857326/ /pubmed/24349876 http://dx.doi.org/10.4161/onci.26441 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Vincent, Marie
Quéméner, Agnès
Jacques, Yannick
Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
title Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
title_full Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
title_fullStr Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
title_full_unstemmed Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
title_short Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
title_sort antitumor activity of an immunocytokine composed of an anti-gd2 antibody and the il-15 superagonist rli
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857326/
https://www.ncbi.nlm.nih.gov/pubmed/24349876
http://dx.doi.org/10.4161/onci.26441
work_keys_str_mv AT vincentmarie antitumoractivityofanimmunocytokinecomposedofanantigd2antibodyandtheil15superagonistrli
AT quemeneragnes antitumoractivityofanimmunocytokinecomposedofanantigd2antibodyandtheil15superagonistrli
AT jacquesyannick antitumoractivityofanimmunocytokinecomposedofanantigd2antibodyandtheil15superagonistrli

Ejemplares similares